1. COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.
- Author
-
Longobardo A, Snow TAC, Montanari C, Shulman R, Singer M, and Arulkumaran N
- Subjects
- Adult, Aged, C-Reactive Protein drug effects, Female, Humans, Hydrocortisone therapeutic use, London epidemiology, Male, Methylprednisolone therapeutic use, Middle Aged, Phenotype, Respiratory Mechanics, Retrospective Studies, SARS-CoV-2, Anti-Inflammatory Agents therapeutic use, COVID-19 physiopathology, Respiratory Distress Syndrome drug therapy, Respiratory Distress Syndrome physiopathology, Steroids therapeutic use, COVID-19 Drug Treatment
- Abstract
Patients with COVID-19 ARDS have distinct physiological and immunological phenotypes compared to patients with non-COVID ARDS. Patients with COVID-19 ARDS (n = 32) had a significant improvement in PaO
2 : FiO2 ratio (p = 0.046) following low-dose steroid treatment, unlike patients with non-COVID ARDS (n = 16) (p = 0.529). Patients with COVID-19 ARDS had a greater fall in CRP compared to patients with non-COVID ARDS, albeit not statistically significant (p = 0.07). Our novel findings highlight differences in the underlying physiological and immunological phenotypes between COVID-19 and non-COVID ARDS, with implications for future ARDS studies., Competing Interests: Declaration of Competing Interest None., (Copyright © 2020 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF